Equillium, Inc., formerly Attenuate Biopharmaceuticals, Inc., was incorporated in Delaware on March 16, 2017. The company is a clinical-stage biotechnology company that leverages a deep understanding of immunobiology to develop new therapies to treat severe autoimmune and inflammatory, or immuno-inflammatory diseases with high unmet medical needs. The company's strategy is focused on advancing the clinical development of product candidates, including potentially pursuing additional indications and acquiring new product candidates and platforms to expand the pipeline. The company intends to commercialize product candidates independently or through partnerships, or monetize the company's pipeline through strategic transactions. 

Expected P&L on Expiry

Key Stats

Pricing Model

About EQ20260417P1